CellMed AG Report issue

For profit Phase 1 Phase 2
Founded: Alzenau Germany (2000)
Status: Acquired by BTG (2005) → now Boston Scientific Corporation (2018)

Organization Overview

First Clinical Trial
2010
NCT01456065
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

Key: CellMed AG (0) Acquired (1)

brivudine phosphoramidate (1 trial)

Drugs in Phase 1 Trials (1)

survivin-peptide double loaded dendritic cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Ovarian Epithelial (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 2